GlassScriptPhysician profile
Danny W Fillip
NPI 1992745053
$11,188.75
in general payments reported to CMS, 2019-2025
42 companies · $3,972 in 2025
The $3,972 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $628 · 2023: $2,788 · 2024: $3,800 · 2025: $3,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,560.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,448.15 | 2022-2025 | |
| Novo Nordisk INC | $1,028.63 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $819.41 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $721.41 | 2022-2025 | |
| Lilly USA, LLC | $680.95 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $584.66 | 2022-2025 | |
| Axsome Therapeutics, INC. | $568.93 | 2023-2025 | Auvelity, Symbravo |
| Astrazeneca Pharmaceuticals LP | $495.35 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $459.92 | 2023-2025 | Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $438.97 | 2024-2025 | Fanapt, Hetlioz |
| Pfizer INC. | $432.44 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $422.24 | 2022-2025 | Jardiance, Ofev, Tradjenta |
| Lundbeck LLC | $417.62 | 2023-2025 | Rexulti, Vyepti |
| Supernus Pharmaceuticals, INC. | $302.78 | 2023-2024 | Qelbree, Xyosted, Tlando |
| Teva Pharmaceuticals USA, INC. | $243.94 | 2022-2025 | Uzedy, Austedo Xr, Ajovy |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $208.59 | 2024-2025 | Voquezna |
| Amgen INC. | $199.94 | 2022-2025 | Repatha, Evenity, Prolia |
| Idorsia Pharmaceuticals US INC | $196.38 | 2023-2025 | Quviviq, Quviviq |
| Kowa Pharmaceuticals America, INC. | $194.99 | 2023-2025 | Livalo, Seglentis, Zoryve |
| Corcept Therapeutics | $167.28 | 2022-2025 | Korlym |
| Mylan Specialty L.P. | $138.88 | 2022-2023 | Yupelri |
| Exact Sciences Corporation | $111.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $106.81 | 2025 | Gemtesa |
| Acella Pharmaceuticals, LLC | $103.74 | 2023-2025 | NP Thyroid 60 |
| Corium, LLC | $100.90 | 2023 | Azstarys |
| Noven Therapeutics, LLC | $64.45 | 2023-2025 | Secuado, Xelstrym |
| Neurocrine Biosciences, INC. | $63.83 | 2022-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $57.98 | 2024-2025 | Cobenfy |
| Nevro Corp. | $51.70 | 2022 | |
| Almatica Pharma LLC | $48.47 | 2023-2024 | Loreev Xr, Gralise |
| Abbott Laboratories | $39.56 | 2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $38.82 | 2023 | Nexletol |
| Tonix Medicines, INC. | $37.38 | 2025 | Tonmya |
| Glaxosmithkline, LLC. | $34.20 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.61 | 2022-2023 | Xifaxan |
| Eisai INC. | $25.13 | 2025 | |
| Halozyme INC | $23.22 | 2023 | |
| Aimmune Therapeutics, INC. | $18.01 | 2024 | |
| Nestle Healthcare Nutrition INC. | $15.25 | 2023 | |
| Calliditas Therapeutics US INC. | $14.54 | 2023 | Tarpeyo |
| Vivus LLC | $14.44 | 2024 | Qsymia |
| Tolmar, INC. | $14.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Fillip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.